33 related articles for article (PubMed ID: 29229225)
1. Structure-Based Design of A-1293102, a Potent and Selective BCL-X
Tao ZF; Wang X; Chen J; Ingram JP; Jin S; Judge RA; Kovar PJ; Park C; Sun C; Wakefield BD; Zhou L; Zhang H; Elmore SW; Phillips DC; Judd AS; Leverson JD; Souers AJ
ACS Med Chem Lett; 2021 Jun; 12(6):1011-1016. PubMed ID: 34141086
[TBL] [Abstract][Full Text] [Related]
2. Discovery of the Clinical Candidate Sonrotoclax (BGB-11417), a Highly Potent and Selective Inhibitor for Both WT and G101V Mutant Bcl-2.
Guo Y; Xue H; Hu N; Liu Y; Sun H; Yu D; Qin L; Shi G; Wang F; Xin L; Sun W; Zhang F; Song X; Li S; Wei Q; Guo Y; Li Y; Liu X; Chen S; Zhang T; Wu Y; Su D; Zhu Y; Xu A; Xu H; Yang S; Zheng Z; Liu J; Yang X; Yuan X; Hong Y; Sun X; Guo Y; Zhou C; Liu X; Wang L; Wang Z
J Med Chem; 2024 May; 67(10):7836-7858. PubMed ID: 38695063
[TBL] [Abstract][Full Text] [Related]
3. Substituted arylsulphonamides as inhibitors of perforin-mediated lysis.
Spicer JA; Miller CK; O'Connor PD; Jose J; Huttunen KM; Jaiswal JK; Denny WA; Akhlaghi H; Browne KA; Trapani JA
Eur J Med Chem; 2017 Sep; 137():139-155. PubMed ID: 28582670
[TBL] [Abstract][Full Text] [Related]
4. Development of a more highly selective M(1) antagonist from the continued optimization of the MLPCN Probe ML012.
Melancon BJ; Lamers AP; Bridges TM; Sulikowski GA; Utley TJ; Sheffler DJ; Noetzel MJ; Morrison RD; Daniels JS; Niswender CM; Jones CK; Conn PJ; Lindsley CW; Wood MR
Bioorg Med Chem Lett; 2012 Jan; 22(2):1044-8. PubMed ID: 22197142
[TBL] [Abstract][Full Text] [Related]
5. Deconstructing Protein Binding of Sulfonamides and Sulfonamide Analogues.
Purder PL; Meyners C; Sugiarto WO; Kolos J; Löhr F; Gebel J; Nehls T; Dötsch V; Lermyte F; Hausch F
JACS Au; 2023 Sep; 3(9):2478-2486. PubMed ID: 37772190
[TBL] [Abstract][Full Text] [Related]
6. Targeting the anti-apoptotic Bcl-2 family proteins: machine learning virtual screening and biological evaluation of new small molecules.
Valentini E; D'Aguanno S; Di Martile M; Montesano C; Ferraresi V; Patsilinakos A; Sabatino M; Antonini L; Chiacchiarini M; Valente S; Mai A; Colotti G; Ragno R; Trisciuoglio D; Del Bufalo D
Theranostics; 2022; 12(5):2427-2444. PubMed ID: 35265218
[TBL] [Abstract][Full Text] [Related]
7. Galacto-conjugation of Navitoclax as an efficient strategy to increase senolytic specificity and reduce platelet toxicity.
González-Gualda E; Pàez-Ribes M; Lozano-Torres B; Macias D; Wilson JR; González-López C; Ou HL; Mirón-Barroso S; Zhang Z; Lérida-Viso A; Blandez JF; Bernardos A; Sancenón F; Rovira M; Fruk L; Martins CP; Serrano M; Doherty GJ; Martínez-Máñez R; Muñoz-Espín D
Aging Cell; 2020 Apr; 19(4):e13142. PubMed ID: 32233024
[TBL] [Abstract][Full Text] [Related]
8. Identification of molecular features necessary for selective inhibition of B cell lymphoma proteins using machine learning techniques.
Mani-Varnosfaderani A; Neiband MS; Benvidi A
Mol Divers; 2019 Feb; 23(1):55-73. PubMed ID: 30003455
[TBL] [Abstract][Full Text] [Related]
9. Selective Bcl-2 inhibition to treat chronic lymphocytic leukemia and non-Hodgkin lymphoma.
Ng SY; Davids MS
Clin Adv Hematol Oncol; 2014 Apr; 12(4):224-9. PubMed ID: 25003352
[TBL] [Abstract][Full Text] [Related]
10. Selective inhibitors of Bcl-2 and Bcl-xL: Balancing antitumor activity with on-target toxicity.
Hennessy EJ
Bioorg Med Chem Lett; 2016 May; 26(9):2105-14. PubMed ID: 26988306
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and pharmacological evaluation of new acyl sulfonamides as potent and selective Bcl-2 inhibitors.
Liu X; Zhang Y; Huang W; Tan W; Zhang A
Bioorg Med Chem; 2018 Jan; 26(2):443-454. PubMed ID: 29229225
[TBL] [Abstract][Full Text] [Related]
12. Discovery of potent and selective Bcl-2 inhibitors with acyl sulfonamide skeleton.
Wang B; Feng W; Wang J; Dong Y; Liu Y; Yao Y; Zhang J; Shi W; Liu L; Zhang H; He X; Chang X; Wang X; Xu H; Liu F; Feng J
Bioorg Med Chem; 2021 Oct; 47():116350. PubMed ID: 34536651
[TBL] [Abstract][Full Text] [Related]
13. Development of 3-phenyl-N-(2-(3-phenylureido)ethyl)-thiophene-2-sulfonamide compounds as inhibitors of antiapoptotic Bcl-2 family proteins.
Yang C; Chen S; Zhou M; Li Y; Li Y; Zhang Z; Liu Z; Ba Q; Li J; Wang H; Yan X; Ma D; Wang R
ChemMedChem; 2014 Jul; 9(7):1436-52. PubMed ID: 24782462
[TBL] [Abstract][Full Text] [Related]
14. Towards the next generation of dual Bcl-2/Bcl-xL inhibitors.
Varnes JG; Gero T; Huang S; Diebold RB; Ogoe C; Grover PT; Su M; Mukherjee P; Saeh JC; MacIntyre T; Repik G; Dillman K; Byth K; Russell DJ; Ioannidis S
Bioorg Med Chem Lett; 2014 Jul; 24(14):3026-33. PubMed ID: 24881567
[TBL] [Abstract][Full Text] [Related]
15. Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL.
Bruncko M; Oost TK; Belli BA; Ding H; Joseph MK; Kunzer A; Martineau D; McClellan WJ; Mitten M; Ng SC; Nimmer PM; Oltersdorf T; Park CM; Petros AM; Shoemaker AR; Song X; Wang X; Wendt MD; Zhang H; Fesik SW; Rosenberg SH; Elmore SW
J Med Chem; 2007 Feb; 50(4):641-62. PubMed ID: 17256834
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
